Standout Papers

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-C... 2019 2026 2021 2023 1.1k
  1. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater (2019)
    Martin Reck, Delvys Rodríguez‐Abreu et al. Journal of Clinical Oncology

Immediate Impact

5 by Nobel laureates 36 from Science/Nature 59 standout
Sub-graph 1 of 22

Citing Papers

Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours
2024 Standout
Hot and cold tumors: Immunological features and the therapeutic strategies
2023 Standout

Works of Antonio Riccio being referenced

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
2019 Standout

Author Peers

Author Last Decade Papers Cites
Antonio Riccio 555 355 178 1049 757 22 2.3k
Marie Brevet 816 138 269 798 1259 75 2.7k
John J. Grygiel 885 89 234 489 945 48 2.4k
Stuart J. Hirst 690 91 198 262 742 36 2.4k
Han Si 1417 280 217 434 418 51 2.6k
Helmut Bonkhoff 1582 406 549 764 2431 79 4.4k
I. Sophie T. Bos 819 80 638 281 709 42 2.2k
Markus Bender 419 322 220 192 439 51 2.1k
Rebecca R. Foster 894 142 207 261 254 46 2.2k
James Deeds 1494 407 290 670 103 24 2.5k
Thomas De Raedt 1062 84 161 279 684 30 2.3k

All Works

Loading papers...

Rankless by CCL
2026